Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386218 | 0.86 | KDM4E (0.43) | KDM4ECYP1A2CYP3A4MAPTPKM | |
| SCHEMBL3570043 | 0.85 | BRD4 (0.43) | KDM4ECYP1A2CYP3A4MAPTPKM | |
| SCHEMBL3571932 | 0.85 | KDR (0.38) | KDM4ECYP1A2CYP3A4MAPTPKM | |
| SCHEMBL3571934 | 0.85 | KDR (0.38) | KDM4ECYP1A2CYP3A4MAPTPKM | |
| SCHEMBL3579883 | 0.82 | MEN1 (0.49) | KDM4ECYP1A2CYP3A4MAPTRAB9A | |
| SCHEMBL3575075 | 0.82 | CCNB2 (0.47) | KDM4ECYP1A2CYP3A4MAPTPKM | |
| SCHEMBL3566184 | 0.79 | MAPT (0.47) | KDM4ECYP1A2CYP3A4MAPTRAB9A | |
| SCHEMBL3575910 | 0.79 | MAPT (0.49) | KDM4ECYP1A2CYP3A4MAPTRAB9A | |
| SCHEMBL3577091 | 0.78 | KMT2A (0.48) | KDM4ECYP3A4MAPTRAB9AALDH1A1 | |
| SCHEMBL2386231 | 0.75 | ALDH1A1 (0.43) | KDM4EMAPTPKMRAB9AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812165-B2 | 6-substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1742947-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108398-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | PNPO, CYP2D6, DPYD | KDM4E 3074/4885CYP1A2 61/4885CYP3A4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.